Language / Ngôn ngữ:
McKaizer Institute — Longevity & Wellness Science
Rapamycin extends lifespan in every animal model tested and is now in human trials. This guide covers the mTOR pathway, rapamycin protocols, risk-benefit analysis, and what the PEARL trial is revealing about longevity in humans.
60%
increase in median lifespan in mice treated with rapamycin — the most replicated longevity result in laboratory aging science
Table of Contents
- mTOR — The Master Switch Between Growth and Longevity
- Rapamycin’s Lifespan Extension — From Yeast to Mammals
- How Rapamycin Works at the Molecular Level
- Human Trials — The PEARL Study and What It Shows
- Rapamycin Protocols — Dosing, Cycling, and Risks
- Alternatives to Rapamycin — Berberine, Acarbose, Torin
- Monitoring mTOR Inhibition — Biomarkers to Track
- The Future of mTOR-Targeted Longevity Medicine
- Frequently Asked Questions (20)
mTOR — The Master Switch Between Growth and Longevity

Rapamycin’s Lifespan Extension — From Yeast to Mammals

“mTOR is the master regulator of aging. Rapamycin is the most robust longevity intervention we know of in mammals — the question now is whether it translates to humans.”
How Rapamycin Works at the Molecular Level

Human Trials — The PEARL Study and What It Shows

Rapamycin Protocols — Dosing, Cycling, and Risks

Alternatives to Rapamycin — Berberine, Acarbose, Torin

Monitoring mTOR Inhibition — Biomarkers to Track

The Future of mTOR-Targeted Longevity Medicine

✦ McKaizer Institute Protocol
Evidence-ranked, actionable steps distilled from the research above.
- Step 1: See the detailed protocol section above.
- Step 2: See the detailed protocol section above.
- Step 3: See the detailed protocol section above.
- Step 4: See the detailed protocol section above.
- Step 5: See the detailed protocol section above.









Leave A Comment